Your session is about to expire
← Back to Search
APATURA Trial Summary
This trial is testing a new drug to see if it is safe and effective for people with asthma who are uncontrolled on medium-to-high dose inhaled corticosteroids and long acting beta agonists. The study will last for 3.5 months and will be conducted at multiple centers.
- Asthma
APATURA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.APATURA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there still vacancies for this research project?
"As indicated on clinicaltrials.gov, enrollment for this medical trial is still taking place. The study was initially announced the 12th of March 2021 and its details were updated last October 21st 2022."
What is the cap on participants involved in this research endeavor?
"Affirmative. According to the details posted on clinicaltrials.gov, this trial is still recruiting participants and was first listed on March 12th 2021. As of October 21st 2022, 225 patients are needed from a single medical site for the study's completion."
Who are the optimal candidates for participation in this experiment?
"The clinical trial is seeking 225 participants who have been diagnosed with asthma, and are between the ages of 18-75."
Has the FDA sanctioned AZD1402 for use?
"AZD1402's safety has been partially established in clinical trials, thus it was assessed a 2 on our team's 1-3 scale. No efficacy data is available for this treatment yet."
Is the age restriction for this experiment limited to those under 30 years of age?
"This medical trial is actively seeking out individuals aged 18 and older, up to the age of 75."
What are the core objectives of this experiment?
"In accordance with the information provided by AstraZeneca, this trial will assess two primary outcomes across a Baseline and Week 4 interval: number of participants experiencing adverse events (AEs) as well as proportion of patients whose ACQ 6 score decreases 0.5 or more from baseline to Week 4. Furthermore, maximum observed plasma concentration divided by dose administered (Dose normalised Cmax) is also being investigated in order to understand the pharmacokinetics profile of AZD1402 (Part 1: full profile in all participants; Part 2: sparse in all, full profile in a subset of participants). These metrics are expected to provide"
Share this study with friends
Copy Link
Messenger